Published in final edited form as:

J Med Chem. 2012 June 28; 55(12): 5987. doi:10.1021/jm300728g.

Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold

Reference citation of paper to be corrected: *J. Med. Chem.* **2012**, *55*, 4664–4682. Haibin Zhou, Jianfang Chen, Jennifer L. Meagher, Chao-Yie Yang, Angelo Aguilar, Liu Liu, Longchuan Bai, Xin Cong, Qian Cai, Xueliang Fang, Jeanne A. Stuckey, and Shaomeng Wang* : Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold.

Page 4667. Figure 4A and 4B were inadvertently interchanged. The correct Figure 4 is shown below. We acknowledge Dr. Asim K. Debnath for pointing out this error.

Figure 4. Structure-based design of a new scaffold as the initial lead compound **4** and its crystal structure in complex with Bcl-xL. (A, B) Rank 1 pose of (A) Lipitor and (B) Celecoxib with BclxL, using the BAD BH3 peptide-bound Bcl-xL structure (PDB ID 2BZW). (C) Identification of the core scaffold from the FDA-approved drugs database for a new class of Bcl-2/Bcl-xL inhibitors. (D) Co-crystal structure of **4** in complex with Bcl-xL (1.7 Å).